# Future Fields

**Source:** https://geo.sig.ai/brands/future-fields  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** futurefields.io  
**Last Updated:** 2026-04-14

## Summary

Precision fermentation biotech producing animal-free growth factors for cultivated meat and cell therapy; Drosophila expression system enabling lower-cost recombinant protein production.

## Company Overview

Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.\n\nFuture Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.\n\nIn 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.

## Frequently Asked Questions

### What is Future Fields?
Future Fields is a biotechnology company founded in 2018 in Edmonton, Alberta, Canada that produces proteins for cultivated meat, biopharma, food, and agriculture. The company uses proprietary EntoEngine™ technology that turns transgenic fruit flies into biofactories, reducing protein production costs by 1,000x compared to conventional methods.

### What products and services does Future Fields offer?
Future Fields offers EntoEngine™ fruit fly biomanufacturing technology, cultivated meat growth factors, biopharma protein production, agricultural biotechnology solutions, and food innovation proteins. Their platform serves multiple industries including biotech, pharma, food, and agriculture.

### Who are Future Fields' customers?
Future Fields serves agricultural leaders, food innovators, and biopharma companies working on cancer and immune therapies. Their client base spans multiple industries requiring cost-effective protein production.

### When was Future Fields founded and by whom?
Future Fields was founded in 2018 by Matt and Jalene Anderson-Baron. The company participated in Y Combinator's Winter 2020 batch.

### Where is Future Fields located?
Future Fields is based in Edmonton, Alberta, Canada. The company opened its first commercial facility in December 2024.

### How much funding has Future Fields raised?
Future Fields has raised $22.4M in total funding over multiple rounds. Their oversubscribed $8M Series A round in June 2025 was co-led by Amplify Capital, BDC Climate Tech Fund, and R7 Partners, with backing from Toyota Ventures, BoxOne Ventures, Builders VC, TRAC VC, and University of Alberta Innovation Fund.

### What are Future Fields' key achievements?
Future Fields has achieved a 1,000x cost reduction compared to legacy protein production platforms and opened its first commercial facility in December 2024. The company is capital efficient and expects to reach profitability with their Series A funding.

### How does Future Fields' EntoEngine™ technology work?
EntoEngine™ technology uses transgenic fruit flies as biofactories to produce proteins at dramatically lower costs. This proprietary approach reduces production costs by 1,000x compared to conventional protein manufacturing methods.

### How has Future Fields' business focus evolved?
Future Fields originally focused on producing growth factors for cultivated meat but has since pivoted to a broader scope. The company now serves biopharma, food, and agriculture industries with its protein production technology.

### What recent developments has Future Fields announced?
In December 2024, Future Fields opened its first commercial facility. In June 2025, the company closed an oversubscribed $8M Series A funding round, bringing total funding to $22.4M.

## Tags

healthtech, saas, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*